Web Stats Provided By Google Analytics

Tuesday, April 22, 2014

New hope for Duchenne muscular dystrophy drug

Sarepta Therapeutics Inc's shares soared 64 percent after it said that the U.S. Food and Drug Administration indicated an alternate path to approval for the company's experimental muscle disorder drug.

http://ift.tt/1rdSu11

No comments:

Post a Comment

Popular Healthcare Law Roundup Posts